German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
Portfolio Pulse from Vandana Singh
Boston Scientific Corporation (NYSE:BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment for patients with atrial fibrillation. The study demonstrated that the FARAPULSE PFA System was non-inferior to standard-of-care therapies, meeting the primary efficacy and safety endpoints. The potential FDA approval of Farapulse might bolster Boston Scientific's position in the electrophysiology market. BSX shares are up 5.54% at $53.57.
August 28, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific's FARAPULSE PFA System shows promise in ADVENT trial, potentially strengthening its position in the electrophysiology market. BSX shares are up 5.54%.
The positive results from the ADVENT trial of the FARAPULSE PFA System could potentially lead to FDA approval, which would strengthen Boston Scientific's position in the electrophysiology market. This positive news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100